



## GUILLAIN-BARRÉ SYNDROME AMID THE CORONAVIRUS DISEASE 2019 ERA

Dear Editor,

We would like to share ideas on the publication “Guillain-Barré Syndrome (GBS) in Mexico: An Updated Review Amid the Coronavirus Disease 2019 ERA<sup>1</sup>.” *“The newly developed vaccinations against SARS-CoV-2 have aroused concerns about the potential danger of developing GBS<sup>1</sup>,”* Galnares-Olalde et al. stated. In addition, epidemiological investigations have revealed no link between SARS-CoV-2 and GBS development, according to Galnares-Olalde et al.<sup>1</sup>. We agree that the new emerging COVID-19 and mass vaccination against this previously unknown disease bring several concerns on GBS. In general,

any virus infection or immunization can cause neurological complications, including GBS. Because the new disease has only been there for a short time, and the vaccination has only been used for a short time, the data may not be sufficient to draw any conclusions about the clinical association. There is little question that a good surveillance system for COVID-19 and COVID-19 vaccination-related GBS is required. Nonetheless, during a pandemic, practitioners may be focused on the new disease and vaccination, and other disorders that can lead to GBS may be overlooked<sup>2</sup>. In any new instance of GBS, a basic investigation and search for previously identified potential causes of GBS are still required.

### REFERENCES

1. Galnares-Olalde JA, López-Hernández JC, García-Grimshaw M, Valdés-Ferrer SI, Briseño-Godínez ME, de-Sarachaga AJ, et al. Guillain-Barré Syndrome in Mexico: an updated review amid the coronavirus disease 2019 era. Rev Invest Clin. 2022 Online ahead of print.
2. Joob B, Wiwanitkit V. COVID-19 and Guillain-Barré syndrome. Rev Neurol (Paris). 2020;17:637.

RUJITTICA MUNGMUNPUNTIPANTIP<sup>1\*</sup> AND VIROJ WIWANITKIT<sup>2</sup>

<sup>1</sup>Private Academic Consultancy, Bangkok, Thailand; <sup>2</sup>Patil University, Pune, Maharashtra, India

**\*Corresponding author:**  
Rujittika Mungmunpantipantip  
E-mail: rujittika@gmail.com

Received for publication: 29-03-2022  
Approved for publication: 20-04-2022  
DOI: 10.24875/RIC.22000081

0034-8376 / © 2022 Revista de Investigación Clínica. Published by Permanyer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).